The Physics of Profit: Why Next-Gen Biologics Are Breaking the Autoinjector

PALM SPRINGS, CA – October 06, 2026 – In the high-stakes arena of global biopharmaceuticals, a quiet crisis of physics is threatening to derail billions of dollars in therapeutic innovation. The industry has successfully engineered a new generation of miraculous, high-dose biologics designed to treat complex chronic conditions. Yet, as these molecules move from the laboratory to the living room, they are colliding with a fundamental mechanical limit: they are simply too thick, and required in too high a volume, for traditional delivery devices to handle.

Today, at the Parenteral Drug Association (PDA) Universe of Pre-Filled Syringes and Injection Devices Conference in Palm Springs, the focus has shifted entirely from the molecules themselves to the mechanics of getting them into the human body. Phillips Medisize, a contract development and manufacturing organization (CDMO) operating under the Molex and Koch Inc. umbrella, alongside U.K.-based Crux Product Design, took the podium to present a stark reality check. Their newly unveiled evidence-based decision-making framework argues that the era of treating drug formulation and device engineering as separate silos is definitively over.

As the pharmaceutical sector races to transition therapies from costly intravenous (IV) hospital infusions to at-home subcutaneous (SC) injections, the engineering hurdles have scaled exponentially. The market is learning a difficult lesson: a groundbreaking biologic is only as profitable as its delivery mechanism is reliable.

Beyond the Spring: The Physics of High-Dose Biologics

For decades, the standard for subcutaneous self-administration was the spring-driven autoinjector, a reliable workhorse designed to deliver fluid volumes between 1 and 2 milliliters. But the thermodynamics and rheological boundaries of modern medicine have changed. To achieve therapeutic efficacy without requiring patients to endure continuous IV drips, drug developers are concentrating biologics to unprecedented levels—often exceeding 200 milligrams per milliliter.

This concentration yields highly viscous formulations that behave less like water and more like syrup. When pharmaceutical companies attempt to force these thick solutions through the narrow gauge of a standard autoinjector needle, the physics break down. The injection force required spikes dramatically, leading to prolonged injection times, mechanical failure, and in severe cases, the shattering of the glass primary container.

Furthermore, even with high concentrations, dose volumes are creeping upward, pushing past the 3 mL threshold. At these volumes, a rapid, spring-loaded injection causes significant tissue distension, resulting in acute pain for the patient.

“High-dose and high-concentration biologics are fundamentally changing the drug delivery landscape,” noted Tony Bedford, Director of Global Research & Development at Phillips Medisize, during the conference presentation. “Success depends on looking at device design, formulation and patient experience together as one connected system from day one. It requires practical, evidence-based choices throughout clinical development to avoid costly delays and scale therapies effectively.”

De-Risking the Pipeline Through Early 'Systems Thinking'

The presentation by Bedford and Tim Quigg, Development Director at Crux Product Design, underscored a critical strategic shift for biopharma executives: de-risking combination products requires early, multidisciplinary alignment. Historically, pharmaceutical sponsors would lock in a drug formulation before tossing it over the wall to device engineers, expecting them to build an autoinjector around it.

Today, that linear approach is a recipe for commercial disaster. Late-stage clinical failures caused by device incompatibility can cost pharmaceutical sponsors hundreds of millions of dollars in delays and lost market exclusivity.

The framework introduced by Phillips Medisize and Crux advocates for "systems thinking" from the earliest stages of clinical development. By utilizing rapid testing and iterative optimization, development teams can evaluate delivery pathways ranging from standard autoinjectors to advanced electromechanical systems and wearable on-body injectors. Crux Product Design, established in 2003 and boasting a multidisciplinary team of over 100 specialists, reportedly collaborates with 18 of the top 20 pharmaceutical companies. They bring critical human factors and applied science expertise to this equation, ensuring that the physical limitations of the drug do not compromise the end-user experience.

This integrated approach is becoming a vital commercial moat. As Phillips Medisize expands its global footprint across 30 manufacturing sites—highlighted by its recent 2025 acquisition of inhalation specialist Vectura—the demand for CDMOs that can offer end-to-end solutions combining formulation insight, device engineering, and global manufacturing scale is surging.

The Wearable Revolution and Patient Economics

As the volume of subcutaneous therapies stretches beyond 3 mL and approaches figures as high as 50 mL, the industry is being forced to abandon the handheld autoinjector entirely in favor of On-Body Delivery Systems (OBDS), or wearable injectors. The economic implications of this transition are staggering. Market analysts project the global wearable injectors market, valued at roughly $11.9 billion in 2025, will skyrocket to over $50 billion by 2034.

The competitive landscape for these large-volume delivery systems is intensely fierce. Device manufacturers and integrated solution providers are locked in an arms race to capture market share. Ypsomed has pushed the boundaries of handheld devices with its YpsoMate 5.5, while companies like BD and West Pharmaceutical Services are aggressively innovating in the high-viscosity space.

Meanwhile, pure-play wearable competitors like Enable Injections are gaining immense traction with devices like the enFuse, which allows for the hands-free, slow infusion of large volumes over extended periods. Enable Injections recently partnered with Aptar Digital Health to deliver companion digital solutions, highlighting how connectivity is becoming intertwined with physical delivery.

The strategic pivot toward wearables is not merely about mechanical necessity; it is deeply rooted in patient economics. A drug that is painful or difficult to administer at home will inevitably suffer from poor patient adherence. In the chronic disease market, non-adherence translates directly to diminished therapeutic outcomes and lost recurring revenue.

A New Commercial Reality for Combination Products

The regulatory environment is also tightening around usability. The U.S. Food and Drug Administration's September 2023 guidance on Human Factors Engineering for combination products mandates rigorous Use-Related Risk Analysis. Regulators now expect sponsors to prove that a patient can safely and comfortably administer a highly viscous drug without critical use errors.

For on-body systems, this means engineering devices that are intuitive to apply, adhere reliably to the skin, provide clear feedback during the delivery cycle, and automatically retract the needle upon completion. The slower, sustained delivery profiles of these electromechanical wearables mitigate the pain of tissue distension, effectively balancing the required therapeutic volume with a tolerable patient experience.

The insights shared by Phillips Medisize and Crux Product Design in Palm Springs signal a maturation of the drug delivery sector. Device choice is no longer a downstream afterthought dictated by volume alone. It is a foundational strategic decision that dictates the viability of the therapy itself. In the modern biopharma landscape, the companies that will capture the lion's share of profit are those that recognize that the container is now just as critical as the cure.